A neurotrophic rationale for the therapy of neurodegenerative disorders

Current Alzheimer Research

Volumn 6, Issue 5, 2009, Pages 419-423

  Saragovi, H Uri ^a   Hamel, Edith ^b   Di Polo, Adriana ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIN RECEPTOR; NEUROTROPHIN RECEPTOR P75; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE A AGONIST; PROTEIN TYROSINE KINASE C; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GLAUCOMA; INTRAOCULAR HYPERTENSION; NERVE DEGENERATION; NERVE FIBER TRANSECTION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; COGNITION DISORDERS; GLAUCOMA; HUMANS; NERVE GROWTH FACTORS; OPTIC NERVE INJURIES; RECEPTORS, NERVE GROWTH FACTOR;

EID: 70249096607     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509789207912     Document Type: Conference Paper

References (48)

1. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10(3): 381-391 (2000).
2. Miller FD, Kaplan DR. Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 58: 1045-1053 (2001).
3. Miller FD, Kaplan DR. Neurobiology. TRK makes the retrograde. Science 295(5559): 1471-1473 (2002).
4. Cuello A. Effects of trophic factors on the CNS cholinergic phenotype. Prog Brain Res 109: 347-358 (1996). (Pubitemid 27047103)
5. Angelucci F, Mathe AA, Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res 146: 151-165 (2004). (Pubitemid 37541382)
6. Duberley RM, Johnson IP, Anand P, Leigh PN, Cairns NJ. Neurotrophin-3-like immunoreactivity and Trk C expression in human spinal motoneurones in amyotrophic lateral sclerosis. J Neurol Sci 148(1): 33-40 (1997). (Pubitemid 27149522)
7. Nagappan G, Lu B. Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications. Trends Neurosci 28(9): 464-471 (2005). (Pubitemid 41187795)
8. Zhou L, Baumgartner BJ, Hill-Felberg SJ, McGowen LR, Shine HD. Neurotrophin-3 expressed in situ induces axonal plasticity in the adult injured spinal cord. J Neurosci 23(4): 1424-1431 (2003). (Pubitemid 36258921)
9. Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 8(8): 1069-1077 (2005). (Pubitemid 41061518)
10. Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron 33(1): 9-12 (2002).
11. Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol 12(3): 260-267 (2002).
12. Lowry KS, Murray SS, Coulson EJ, Epa R, Bartlett PF, Barrett G, et al. Systemic administration of antisense p75(NTR) oligodeoxynucleotides rescues axotomised spinal motor neurons. J Neurosci Res 64(1): 11-17 (2001). (Pubitemid 32267989)
13. Peleshok J, Saragovi HU. Functional mimetics of neurotrophins and their receptors. Biochem Soc Trans 34(Pt 4): 612-617 (2006). (Pubitemid 44230776)
14. Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci 21: 93-98 (2000). (Pubitemid 30114323)
15. Saragovi HU. Progression of age-associated cognitive impairment correlates with quantitative and qualitative loss of TrkA receptor protein in nucleus basalis and cortex. J Neurochem 95(5): 1472-1480 (2005).
16. Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction of p140-TrkA Receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 146: 91-103 (1997). (Pubitemid 27319723)
17. Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 427(1): 19-30 (2000). (Pubitemid 30745433)
18. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 56(4): 520-531 (2004). (Pubitemid 39319342)
19. Sendera TJ, Ma SY, Jaffar S, Kozlowski PB, Kordower JH, Mawal Y, et al. Reduction in TrkA-immunoreactive neurons is not associated with an overexpression of galaninergic fibers within the nucleus basalis in Down's syndrome. J Neurochem 74: 1185-1196 (2000). (Pubitemid 30104316)
20. Pierce R, Bari A. The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci 12: 95-110 (2001). (Pubitemid 32494335)
21. Olanow CW, Freeman T, Kordower J. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Eng J Med 345(2): 146 (2001) discussion 7.
22. Longo FM, Massa SM. Neurotrophin-based strategies for neuroprotection. J Alzheimers Dis 6(6 Suppl): S13-7 (2004).
23. Bechade C, Mallecourt C, Sedel F, Vyas S, Triller A. Motoneuron-derived neurotrophin-3 is a survival factor for PAX2-expressing spinal interneurons. J Neurosci 22(20): 8779-8784 (2002). (Pubitemid 35379046)
24. Haase G, Kennel P, Pettmann B, Vigne E, Akli S, Revah F, et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 3(4): 429-436 (1997). (Pubitemid 27145685)
25. Saragovi HU, Burgess K. Small molecule and protein-based neurotrophic ligands: agonists and antagonists as therapeutic agents. Exp Opin Ther Patents 9: 737-751 (1999). (Pubitemid 29259659)
26. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11(5): 551-555 (2005). (Pubitemid 40691288)
27. Beglova N, LeSauteur L, Ekiel I, Saragovi HU, Gehring K. Solution structure and internal motion of a bioactive peptide derived from nerve growth factor. J Biol Chem 273: 23652-23658 (1998). (Pubitemid 28435693)
28. Beglova N, Maliartchouk S, Ekiel I, Zaccaro MC, Saragovi HU, Gehring K. Design and solution structure of functional peptide mimetics of nerve growth factor. J Med Chem 43: 3530-3540 (2000). (Pubitemid 30736707)
29. LeSauteur L, Wei L, Gibbs B, Saragovi HU. Small Peptide Mimics of Nerve Growth Factor Bind TrkA Receptors and Affect Biological Responses. J Biol Chem 270: 6564-6569 (1995).
30. Maliartchouk S, Debeir T, Beglova N, Cuello A, Gehring K, Saragovi H. Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. J Biol Chem 275: 9946-9956 (2000). (Pubitemid 30202040)
31. Maliartchouk S, Saragovi HU. Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. J Neurosci 17: 6031-6037 (1997). (Pubitemid 27329878)
32. McPhee IJ, Barker PA. BDNF Binding to p75NTR Results in reduced TrkA signaling and increased serine phosphorylation within the TrkA intracellular domain. J Biol Chem 272(38): 23547-23551 (1997).
33. Ivanisevic L, Banerjee K, Saragovi HU. Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75. Oncogene 22(36): 5677-5685 (2003). (Pubitemid 37102704)
34. Bredesen DE, Rabizadeh S. p75NTR and apoptosis: Trk-dependent and Trk-independent effects. Trends Neurosci 20: 287-290 (1997).
35. Bredesen DE, Ye X, Tasinato A, Sperandio S, Wang JJ, Assa-Munt N, et al. p75NTR and the concept of cellular dependence: seeing how the other half die. Cell Death Differ 5: 365-371 (1998). (Pubitemid 28356812)
36. Zaccaro M, Ivanisevic L, Perez P, Meakin S, Saragovi H. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. J Biol Chem 276: 31023-31029 (2001). (Pubitemid 37384966)
37. Ivanisevic L, Zheng W, Woo SB, Neet KE, Saragovi HU. TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand. J Biol Chem 282(23): 16754-16763 (2007).
38. LeSauteur L, Malartchouk S, LeJeune H, Quirion R, Saragovi HU. Potent and specific p140-TrkA agonists derived from an antireceptor monoclonal antibody. J Neurosci 16: 1308-1316 (1996). (Pubitemid 26146986)
39. Esteban PF, Yoon HY, Becker J, Dorsey SG, Caprari P, Palko ME, et al. A kinase-deficient TrkC receptor isoform activates Arf6-Rac1 signaling through the scaffold protein tamalin. J Cell Biol 173(2):291-299 (2006).
40. Maliartchouk S, Feng Y, Ivanisevic L, Debeir T, Cuello AC, Burgess K, et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol 57(2): 385-391 (2000). (Pubitemid 30084516)
41. Pattarawarapan M, Zaccaro MC, Saragovi U, Burgess K. New templates for synthesis of ring-fused C10 b-Turn peptidomimetics leading to the first reported small molecule mimic of neurotrophin-3. J Med Chem 45(20): 4387-4390 (2002).
42. Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, et al. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem Biol 12(9): 1015-1028 (2005). (Pubitemid 41338812)
43. Zhang AJ, Khare S, Gokulan K, Linthicum DS, Burgess K. Dimeric b-turn peptidomimetics as ligands for the neurotrophin receptor receptor TrkC. Bioorg Med Chem Lett 1: 207-210 (2001). (Pubitemid 32099641)
44. Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Dev Neurobiol 67(7): 884-894 (2007). (Pubitemid 47066919)
45. Debeir T, Saragovi HU, Cuello AC. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci 96: 4067-4072 (1999). (Pubitemid 29169037)
46. Bruno MA, Clarke PB, Seltzer A, Quirion R, Burgess K, Cuello AC, et al. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci 24(37): 8009-8018 (2004). (Pubitemid 39280820)
47. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20(11): 4050-4058 (2000). (Pubitemid 30365675)
48. Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A. Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Mol Cell Neurosci 40(4): 410-420 (2009).